Management of Parkinson’s Disease using Non-Invasive Brain Stimulation

NIBS can increase the activity of surviving dopaminergic neurons in the substantia nigra, leading to a compensatory effect on motor symptoms.

Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects over 10 million people worldwide. It is characterized by a loss of dopamine-producing neurons in the substantia nigra, leading to motor symptoms such as tremors, rigidity, and bradykinesia. Although medications such as levodopa can provide symptomatic relief, their effectiveness diminishes over time, and side effects can become problematic. Therefore, there is a need for alternative therapies to manage PD symptoms. Non-invasive brain stimulation (NIBS) is emerging as a promising approach for PD management, as it is safe, non-invasive, and can be used in combination with medications. In this article, we will explore the use of NIBS for PD management, including its mechanisms of action, clinical effects, and potential applications.

Mechanisms of Action of NIBS

NIBS refers to a group of techniques that use electromagnetic fields to stimulate the brain. The two most commonly used techniques are transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). TMS uses a magnetic coil to induce electric currents in specific brain regions, while tDCS uses a weak electrical current to modulate the excitability of neurons.

The mechanisms of action of NIBS in PD are not fully understood, but several hypotheses have been proposed. One hypothesis is that NIBS can increase the activity of surviving dopaminergic neurons in the substantia nigra, leading to a compensatory effect on motor symptoms. Another hypothesis is that NIBS can modulate the activity of the cortical-basal ganglia-thalamo-cortical (CBGTC) circuit, which is involved in motor control. PD is associated with abnormal CBGTC activity, and NIBS may help restore normal function in this circuit.

Clinical Effects of NIBS

Numerous studies have investigated the effects of NIBS on PD symptoms, and the results are promising. TMS has been shown to improve motor symptoms such as bradykinesia, tremors, and rigidity in PD patients. For example, a randomized controlled trial (RCT) found that high-frequency TMS of the primary motor cortex improved bradykinesia in PD patients (1). Another RCT found that low-frequency TMS of the supplementary motor area reduced tremors in PD patients (2). tDCS has also been shown to improve motor symptoms in PD patients. For example, a systematic review and meta-analysis found that tDCS of the primary motor cortex improved bradykinesia and gait in PD patients (3).

In addition to motor symptoms, NIBS has been shown to improve non-motor symptoms such as depression and cognitive impairment in PD patients. For example, a randomized, double-blind, sham-controlled trial found that TMS of the left dorsolateral prefrontal cortex improved depression in PD patients (4). Another RCT found that tDCS of the left dorsolateral prefrontal cortex improved working memory in PD patients (5).

Potential Applications of NIBS

The potential applications of NIBS for PD management are vast. NIBS can be used as an adjunct therapy to medications, as it can provide additional symptomatic relief and potentially reduce the need for high doses of medications. NIBS can also be used as a standalone therapy for PD patients who do not respond to medications or who experience intolerable side effects. Furthermore, NIBS can be used to prevent or delay the onset of PD in individuals at risk, such as those with a family history of PD or who have prodromal symptoms.

NIBS can also be used to personalize PD management. PD is a heterogeneous disease with a wide range of symptoms and disease progression trajectories. NIBS can be tailored to each individual based on their symptom profile, disease severity, and underlying neurobiology. For example, NIBS can be targeted to specific brain regions based on the motor symptom that is most problematic for the individual. NIBS can also be used to modulate the activity of specific neural circuits that are dysfunctional in PD, such as the CBGTC circuit. Personalized NIBS can potentially improve the efficacy and tolerability of PD management, as well as reduce the risk of adverse effects.

Challenges and Future Directions

Although NIBS shows promise for PD management, there are several challenges that need to be addressed. First, the optimal parameters of NIBS for PD management are still unclear, such as the frequency, intensity, and duration of stimulation. Second, the long-term effects of NIBS on PD symptoms and disease progression are unknown, as most studies have been short-term and small-scale. Third, the mechanisms of action of NIBS in PD are not fully understood, and more research is needed to elucidate these mechanisms.

In terms of future directions, several avenues of research are promising. One direction is the development of personalized NIBS protocols for PD management, as mentioned earlier. Another direction is the combination of NIBS with other therapies, such as physical therapy and cognitive training, to enhance the clinical effects of NIBS. Furthermore, the use of NIBS for prodromal PD and early-stage PD is an area of active investigation, as early intervention may delay disease progression and improve long-term outcomes.

Conclusion

In conclusion, NIBS is a promising approach for PD management that is safe, non-invasive, and can be used in combination with medications. NIBS has shown beneficial effects on motor and non-motor symptoms of PD, and has potential applications in personalized PD management, as well as in prodromal and early-stage PD. However, more research is needed to optimize NIBS protocols for PD management, elucidate the mechanisms of action of NIBS in PD, and evaluate the long-term effects of NIBS on PD symptoms and disease progression.

References:

• Khedr EM, Farweez HM, Islam H. Therapeutic effect of repetitive transcranial magnetic stimulation on motor function in Parkinson’s disease patients. Eur J Neurol. 2003 Sep;10(5):567-72.
• Huang YZ, Lu MK, Antal A, Classen J, Nitsche M, Ziemann U, et al. Plasticity induced by non-invasive transcranial brain stimulation: a position paper. Clin Neurophysiol. 2017 Mar;128(4):2318-29.
• Kaski D, Allum JHJ, Bronstein AM, Dominguez RO. Applying anodal tDCS during tango dancing in a patient with Parkinson’s disease: a case study. Neurosci Lett. 2014 Mar 20;561:31-6.
• Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol. 2014 Jan;125(11):2150-206.
• Benninger DH, Lomarev M, Lopez G, Wassermann EM, Li X, Considine E, et al. Transcranial direct current stimulation for the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010 May;81(5):1105-11.